Diabetes Drugs Market, By Diabetes Type (Type 1 and Type 2), By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Others), By Distribution Channel (Online pharmacies, Hospital Pharmacies, and Retail Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Trends, Analysis, and Forecast till 2029

Diabetes, or diabetes mellitus, refers to a metabolic disorder in which an individual experiences high levels of blood glucose. It is usually caused by inadequate insulin production or a faulty response to insulin in the body. This disorder can lead to chronic health problems, such as cardiovascular diseases (CVDs) and renal, nerve and neural damage. Various anti-diabetic medicines, along with self-monitoring, continuous glucose monitoring and insulin delivery devices, are used for diagnosing the disorder and monitoring its effects in the body. Apart from this, numerous software- and web-based diabetes and blood glucose tracking applications and data management platforms are also being widely used across the healthcare sector. The global diabetes drugs market accounted for US$ 51.4 billion in 2019 and is estimated to be US$ 93.6 billion by 2029 and is anticipated to register a CAGR of 6.20%.

Impact of Covid-19 pandemic on market

With the outbreak of the COVID-19, various businesses are at the forefront to combat this pandemic. The pandemic has hindered the industrial supply chain and also disrupted the product segment. Government across the countries has imposed strict lockdown to limit the spread of disease. Due to this pandemic the diabetes drug market have a negative impact. According to a recent study from the Manchester University showed that the number of deaths from type 2 diabetes (T2D) in England more than doubled at the peak of the COVID-19 pandemic in April. The number of T2D diagnosed cases fell by 70% in the same period. This report will quantify the impact of a pandemic on the diabetes drugs market.

Rising prevalence of diabetes

The global diabetes drug market is majorly driven by increasing number of diabetic population. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the diabetes drug market. During last decade there is a tremendous increase in the number of diabetic population. According to International Diabetes Federation, in 2016, it was estimated that 420 million adult populations were suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040.

Increasing government’s initiatives

The government is taking steps to control diabetes also increases the growth of the diabetes drugs market. For instance, WHO estimated that 422 million people globally suffered from diabetes and also indicated that 1.5 million people died from diabetes, which are some of the major factors responsible for the market growth. However, cost issues, strict regulatory rules and long approval time for drugs might be hampering the growth of the diabetes drugs market.

The global diabetes drugs market is segmented based on diabetes type, drug class, distribution channel, and region.

On the basis of diabetes type, the global diabetes drugs market is segmented into type 1 and type 2. Based on drug class, the target market is segmented into insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and others. Based on distribution channel, the target market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies.

Regional Insights:

On region the global diabetes drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the most important market share in 2018 and is anticipated to dominate the market during the forecast period. Growing investments in research and development activities via many government institutions and an increase within the widespread presence of diabetes are a couple of the factors expected to account for the good-sized diabetes drugs market share in North America. Additionally, increasing knowledge about the novel anti-diabetic drugs, the introduction of anti-diabetic drugs, and beneficial reimbursement plans are probable to bolster the diabetic drugs market in North America.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global diabetes drugs market report based on diabetes type, drug class, distribution Channel, and region.

Global Diabetes Drugs Market, By Diabetes Type:

• Type 1
• Type 2

Global Diabetes Drugs Market, By Drug Class:

• Insulin
• DPP-4 Inhibitors
• GLP-1 Receptor Agonists
• SGLT2 Inhibitors
• Others

Global Diabetes Drugs Market, By Distribution Channel:

• Online pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Global Diabetes Drugs Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the global diabetes drugs market includes Eli Lilly, Novo Nordisk, Abbott, AstraZeneca, Biocon, Sunpharma, Sanofi, Novartis, Merck & Co., Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Akros Pharma, Amgen, Adocia, Peptron, and Takeda. The market is especially characterized by collaborations and partnerships between the businesses and acquisitions of smaller players as a part of strategic expansion as well as launching their new product specimen. For instance, In April 2019, Glenmark Pharmaceuticals announced that it plans to bring its Remogliflozin Etabonate to India. The high demand for diabetes drugs in India has influenced Glenmark’s latest move. Additionally, a huge diabetic patient pool has also contributed to the high demand for diabetes drugs in India.

• Eli Lilly
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Novo Nordisk
• Abbott
• AstraZeneca
• Biocon
• Sunpharma
• Sanofi
• Novartis
• Merck & Co.
• Pfizer